Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

Fig. 5

Pain intensity at rest decreased dramatically in the auto-BM-MNC and allo-WJ-MSC-treated diabetic patients with CTLI. Pain decreased in participants treated with auto-BM-MNC or allo-WJ-MSC approaches from the first month compared to the placebo group. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (p < 0.05); placebo group versus allo-WJ-MSC group (*) (p < 0.05); auto-BM-MNC group versus allo-WJ-MSC group (%) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group three months post-treatment (λ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group three months post-treatment (ϕ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group six months post-treatment (φ) (p < 0.05); and allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group twelve months post-treatment (Ω) (p < 0.05). Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512